Management Policies

Message from Leadership

Net sales reached a record high, and business remained strong.

Net sales increased, owing to higher sales in the Americas, EMEA*¹, China, and AP regions

Operating profit was flat despite an improvement in the cost of sales ratio, due to an increase in SG&A expenses and the impact of other operating income (expenses).

February 2024

Kaoru Asano
President

In the first nine months of the fiscal year ending March 31, 2024, the Sysmex Group posted its highest-ever net sales, with the Americas, China, and AP regions posting double-digit year-on-year sales growth and sales in EMEA and Japan remaining on a par with the previous year. Operating profit was flat, however. Although higher net sales and an improved cost of sales ratio pushed up gross profit, SG&A expenses rose due to inflation and the promotion of growth strategies, and we were affected by other operating income (expenses). Profit attributable to owners of the parent was down, owing to an increase in corporate taxes.

Net sales rose 9.3% year on year, operating profit fell 0.3%, and profit attributable to owners of the parent was down 2%. At the exchange rates prevailing one year earlier, net sales would have been up 5.7% and operating profit down 12.6%.

In the diagnostics business, sales rose, owing to higher sales in our major fields of hematology*2, urinalysis, and hemostasis. In our mainstay field of hematology, instrument sales rose in China, as we reinforced our local production system, and in Japan, centered on the sale of new products. Reagent sales were also favorable across all regions, leading to double-digit sales growth in the hematology field. Also in the urinalysis, hemostasis, immunochemistry, and life science fields, sales of reagents and services increased, owing to the expansion of our installed instrument base.

In the medical robotics business, we installed nine units during the period, bring our total to 44. The number of surgeries performed using our system increased by 790 between October and December 2023, bringing the total number of cases to more than 3,300 as of December 31, 2023, pointing to solid growth.

Among major recent topics, in January 2024 we expanded sales to Europe (following on from sales in Japan and the United States) of a blood-based test reagent to check the accumulation of amyloid-β in the brain, which is believed to be a cause of Alzheimer's disease. Going forward, Sysmex will continue to promote activities towards expanding its testing parameters, including assay kits, accelerating the deployment of our immunochemistry testing business in Europe. Sysmex is committed to establishing and promoting testing and diagnostic technologies that put less of a burden on patients, both in Japan and overseas, and on enhancing the quality of life for patients and their families.

I would like to ask our stakeholders for your continued support.

*1 EMEA: Europe, the Middle East, and Africa

*2 Hematology field: The field of in vitro diagnostics that determines whether precise testing is necessary by analyzing the number, type and size of red, white and other blood cells.

Back to "Management Policies"